GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncternal Therapeutics Inc (FRA:GTU) » Definitions » Additional Paid-In Capital

Oncternal Therapeutics (FRA:GTU) Additional Paid-In Capital : €210.77 Mil(As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Oncternal Therapeutics Additional Paid-In Capital?


Oncternal Therapeutics's quarterly additional paid-in capital declined from Sep. 2023 (€211.34 Mil) to Dec. 2023 (€208.92 Mil) but then increased from Dec. 2023 (€208.92 Mil) to Mar. 2024 (€210.77 Mil).

Oncternal Therapeutics's annual additional paid-in capital increased from Dec. 2021 (€178.95 Mil) to Dec. 2022 (€206.98 Mil) and increased from Dec. 2022 (€206.98 Mil) to Dec. 2023 (€208.92 Mil).

Oncternal Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Oncternal Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncternal Therapeutics Additional Paid-In Capital Chart

Oncternal Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 71.88 160.87 178.95 206.98 208.92

Oncternal Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 207.54 206.65 211.34 208.92 210.77

Oncternal Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Oncternal Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Oncternal Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncternal Therapeutics (FRA:GTU) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncternal Therapeutics Inc (FRA:GTU) » Definitions » Additional Paid-In Capital
Comparable Companies
SLGL GDTC UBX SNSE LPCN FBRX SER PYPD CNTX ZIVO OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
ONCT:USA
Address
12230 El Camino Real, Suite 230, San Diego, CA, USA, 92130
Website
https://www.oncternal.com
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.

Oncternal Therapeutics (FRA:GTU) Headlines

No Headlines